NDA 217388 · Astrazeneca Ab
Wainua (Autoinjector)
Eplontersen Sodium · Subcutaneous · Transthyretin-directed RNA Interaction; Antisense Oligonucleotide
NovelOrphanCDER novel approval, Dec 21, 2023: To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Dec 21, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
9
5 Phase 3, 1 recruiting
FAERS reports
175
76 serious, 16 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 15, 2026.
WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. WAINUA is a transthyretin-directed antisense oligonucleotide indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. ( 1 )
Mechanism: Eplontersen is an antisense oligonucleotide-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through binding to the TTR mRNA, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.
Therapeutic areas: Neurology · Rare and genetic disease · Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 15, 2026 Supplement 5 · Efficacy OrphanLetterLabel
- Dec 21, 2023 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
- WAINUA (AUTOINJECTOR) · EPLONTERSEN SODIUM EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription
- WAINUA · EPLONTERSEN SODIUM EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Eplontersen" as an intervention, any sponsor and status, largest first.
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04136171 · 1,438 participants · Start Mar 13, 2020 · Primary completion Mar 25, 2026
Drug: Eplontersen; Placebo · For: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; La Jolla, California; Los Angeles, California · 139 sites in all
- An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Pivotal-lookingEnrolling by invitation
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05667493 · 1,400 participants (planned) · Start Nov 30, 2022 · Primary completion Aug 2029
Drug: Eplontersen · For: Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Sites: Scottsdale, Arizona; Beverly Hills, California; La Jolla, California · 134 sites in all
- A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CMPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07608354 · 326 participants (planned) · Start Jun 11, 2026 · Primary completion Feb 6, 2029
Drug: Eplontersen; ALXN2220 · For: Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Sites: La Jolla, California; San Francisco, California; Stanford, California · 76 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04136184 · 168 participants · Start Dec 11, 2019 · Primary completion Apr 11, 2023
Drug: Inotersen; Eplontersen · For: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Sites: Scottsdale, Arizona; Jacksonville, Florida; Indianapolis, Indiana · 45 sites in all
- A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid PolyneuropathyPivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT05071300 · 151 participants · Start Jan 4, 2022 · Primary completion Aug 2029
Drug: Eplontersen · For: Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Sites: Scottsdale, Arizona; Indianapolis, Indiana; Baltimore, Maryland · 33 sites in all
- EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid CardiomyopathyPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06194825 · 64 participants · Start Dec 1, 2023 · Primary completion May 13, 2026
Drug: Eplontersen; Placebo · For: Transthyretin Amyloid Cardiomyopathy
Sites: Beijing, China; Changsha, China; Chengdu, China · 26 sites in all
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT03728634 · 47 participants · Start Dec 21, 2018 · Primary completion Feb 20, 2020
Drug: ION-682884; Placebo · For: Healthy Volunteers; hATTR Amyloidosis
Sites: Toronto, Canada
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04302064 · 24 participants · Start Apr 23, 2020 · Primary completion Sep 10, 2020
Drug: Eplontersen; Placebo · For: Healthy Participants
Sites: Cypress, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death16
- fatigue13
- nausea13
- neuropathy peripheral13
- pain9
- product dose omission issue7
- vomiting7
- diarrhoea6
- hypoaesthesia6
- pain in extremity6
- paraesthesia6
- vision blurred6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 51 |
| 2025 | 102 |
| 2026 | 22 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Wainua (Eplontersen Sodium)
2024 spending
$56.9M
Beneficiaries
251
1,331 claims
Per beneficiary
$226,539
$52,214.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $56,861,357 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis.
Masri A, Maurer MS, Claggett BL, et al. · J Card Fail 2024 · Clinical Trial, Phase III, Multicenter Study
- Baseline characteristics of patients with transthyretin amyloid cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.
Fontana M, Ambardekar AV, Cappelli F, et al. · Eur J Heart Fail 2026 · Clinical Trial, Phase III, Multicenter Study
- Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.
Masri A, Cappelli F, Davis MK, et al. · Circ Heart Fail 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
- Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial.
Wixner J, Berk JL, Adams D, et al. · Amyloid 2025 · Randomized Controlled Trial
- Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform.
Conceição I, Berk JL, Weiler M, et al. · J Neurol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial.
García-Pavía P, Cappelli F, Davis MK, et al. · Nat Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca · Also marketed as Wainua
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.